GCL
REVBW icon

Glazer Capital LLC’s Revelation Biosciences Warrant REVBW Stock Holding History

Glazer Capital LLC’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-554,552
Closed -$344K – 848
2021
Q3 		$344K Buy
+554,552
New +$336K 0.01% 600

Other funds holding REVBW

OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
ICM
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $54B AUM 23.5% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Glazer Capital LLC's REVBW Position: Q4 2021 in Review

Glazer Capital LLC sold out of Revelation Biosciences Warrant (REVBW) in Q4 2021, closing a stake of 554,552 shares — an estimated $344K sold.

Glazer Capital LLC first reported a position in REVBW in Q3 2021 and held it in 1 quarter. The position peaked at $344K in Q3 2021. 20 funds tracked by Wall St. Rank hold REVBW as of Q4 2021.

  • Glazer Capital LLC reported no remaining Revelation Biosciences Warrant position as of Q4 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 554,552 Revelation Biosciences Warrant shares in Q4 2021, an estimated $344K.
  • Glazer Capital LLC first reported a position in Revelation Biosciences Warrant in Q3 2021 and held it in 1 quarter.
  • Glazer Capital LLC's Revelation Biosciences Warrant position peaked at $344K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q4 2021.

Based on Glazer Capital LLC's 13F filing for Q4 2021, filed 14 Feb 2022.